PS.
PublicSupply
account_balanceBuyersbusinessSuppliersdescriptionNotices
BuyersSuppliersNotices
verified_userData sourced from Contracts Finder, Find a Tender, and Companies House.
Contracts Finder ↗Find a Tender ↗Procurement Act 2023 ↗
  1. Home›
  2. Suppliers›
  3. TEVA UK LIMITED
TU

TEVA UK LIMITED

Castleford
Large

Teva UK Limited is a biopharmaceutical company dedicated to improving the lives of patients by developing innovative medicines, including generics and biosimilars. They focus on providing access to quality medicine that helps manage diseases and improve overall health.

tevauk.com ↗

Summary from the supplier’s website — unverified

Compare peers
Awarded
£2.6bn
Live
126
Buyers
16
12m
£2.2bn
At a glance
  • Quick answer
Profile
  • Social value
  • ESG & policies
  • Capabilities6
  • Buyer references
  • Accreditations
Track record · verified
  • KPI performance
  • Contracts126 / 187
  • Top buyers16
  • Category mix
  • Geography
  • Peers5
Trust & risk
  • Red flags0
  • Compliance
  • Modifications
  • News
Company
  • Companies House
  • Financial
  • Org tree
Quick answer — TEVA UK LIMITEDUpdated 06 Jul 2026

At a glance · for buyers and watchdogs

TEVA UK LIMITED has won £2.6bn across 16 public-sector buyers, with 126 live contracts. No active Companies House risk flags.

Why: top buyer NHS England at 70% · 0 active risk flags · 0 modifications.

Decision signals
0Active red flags
ActiveCompany status
126 of 187Live contracts
70%Top-buyer concentration
—Category exposure
0Contract modifications
If you're a buyer:CapabilitiesReferencesKPIComplianceWatchdog?FlagsModificationsConcentrationNews

Social value · 2/5

Commitments mapped to the Government Social Value Model themes. Each is tagged self-reported or from the website.

◐ From supplier website
JobsNo commitment stated✓
SkillsNo commitment stated✓
Environment1 commitment ↗✓
Tackling inequalityNo commitment stated✓
Community1 commitment ↗✓
Environment · 1
  • WebsiteSustainability InitiativesTeva is committed to sustainability and has a Carbon Reduction Plan.
Community · 1
  • WebsiteOur Contribution to UK HealthcareTeva collaborates with the NHS to improve healthcare delivery and patient outcomes.

Extracted automatically from tevauk.com on Jul 2026. Not independently verified — treat as the supplier’s own marketing claims.

ESG & policies vault · 0/5

Key governance & sustainability policies. Published documents link out; missing ones are greyed.

↔ Cross-checked
Net-zero planNot provided✓
Modern slavery statementNot provided✓
EDI policyNot provided✓
Anti-briberyNot provided✓
Data protectionNot provided✓

Capabilities

What this supplier does, where they sit, who they sell to.

◐ From website & notices
Sectors served · 1/8
Central government✓
Local government✓
NHS & health✓
Housing✓
Utilities & energy✓
Financial services✓
Education✓
Defence✓
Services · 3
Innovative MedicinesDeveloping innovative medicines for the future. ↗Generic MedicinesChampioning the production of high-quality generic medicines. ↗BiosimilarsProducing biosimilar medicines. ↗
Frameworks & DPS · 6 from notices
  • National Microbiology Framework - Lot 1: Diagnostic Goods and ServicesPublic Health England · £25.6m
  • NHS England Framework Agreement: South of England (Tranche B)NHS England · £15.7m
  • NHS Framework Agreement, Branded Medicines for London and South of EnglandNHS England · £13.3m
  • NHS England Framework Agreement - London - Tranche ANHS England · £10.6m
  • NHS Framework Agreement for Proprietary Pharmaceuticals - South of England (Tranche A)NHS England · £10.5m
  • NHS England - Midlands and East Branded Medicines - Tranche BNHS England · £9.2m

Extracted automatically from tevauk.com on Jul 2026. Not independently verified — treat as the supplier’s own marketing claims.

Case studies

Delivery stories the supplier has published, with sector and outcome.

⚑ Self-reported
—

No case studies yet

Once a claimed supplier publishes delivery stories — the buyer, the sector, what was delivered and the outcome — they appear here.

Buyer references

Named public-sector contacts who have agreed to act as a reference.

✓ Confirmed by buyer
—

No buyer references yet

Public-sector buyers can confirm they'll act as a reference for this supplier. Confirmed references — with the contract they relate to — show here.

Accreditations & memberships

Independently issued. Verification dates cross-checked against issuer registers.

↔ Cross-checked
—

No accreditations recorded

B-Corp, ISO, Cyber Essentials, Living Wage and similar credentials appear here once added by a claimed supplier and cross-checked against the issuing register.

KPI performance

Delivery, budget and satisfaction scores reported quarterly by buyers.

✓ Verified
84

No verified KPI scores yet

Once buyers report contract KPIs — delivery on time, on budget, satisfaction, adoption and accessibility — a weighted grade and breakdown appear here.

Contracts · 126 live · 61 historic

Pulled from Contracts Finder & Find a Tender. Most recent first.

✓ From notices
TitleBuyerCPVAwardedValueTermStatus
NHS Branded Medicines - Tranche B - London & South of England - 1 September 2026
NHS England—01 Sept 2026£813.9m2 yrspending
NHS National Generics Pharmaceuticals - Supply Chain Resilience
NHS England—01 Sept 2026£4.2m1.8 yrspending
NHS National Branded Interim - 1 June 2026
NHS England—01 Jun 2026£529.1m1.9 yrspending
NHS Generic Pharmaceuticals - Lenalidomide, Pomalidomide & Thalidomide
NHS England—01 Jun 2026£19.6m2 yrspending
Transitional Drugs 6
NHS Wales Shared Services Partnership-Procurement Services (hosted by Velindre University NHS Trust)—01 Mar 2026£1.6m2 yrspending
NHS National Generic Pharmaceuticals - Wave 15c
NHS England—01 Jun 2026£17.7m12 mopending
NHS National Transition Framework for Apremilast, Pazopanib and Dapagliflozin
NHS England—01 Feb 2026£25.9m1.7 yrspending
Transitional Drugs 5
NHS Wales Shared Services Partnership-Procurement Services (hosted by Velindre University NHS Trust)—01 Jan 2026£5.6m2 yrspending
NHS National Framework for Generics Housekeeping
NHS England—01 Feb 2026£21.6m1.7 yrspending
Project/Contract NHS National Framework for Denosumab Injection
NHS England—01 Jan 2026£37.7m12 mopending
Total live value £51.7m · mean award £14.1m1–10 of 187

Top buyers · 16 buyers · top 3 = 98%

Share of awarded value. Concentration fires above 40% for any single buyer.

✓ From notices
1
NHS England
93 contracts
70%
since 2017
2
NHS England North East and Yorkshire Health and Justice
1 contract
26%
since 2025
3
Public Health England
4 contracts
2%
since 2021
4
Department of Health and Social Care (T&T)
8 contracts
1%
since 2020
5
NHSE&I
1 contract
1%
since 2022
6
NHS Wales Shared Services Partnership-Procurement Services (hosted by Velindre University NHS Trust)
4 contracts
0%
since 2025
7
NHS England and NHS Improvement
1 contract
0%
since 2022
8
The Common Services Agency (more commonly known as NHS National Services Scotland) (NSS)
41 contracts
0%
9
Procurement and Logistics Service, Business Services Organisation
2 contracts
0%
10
The NHS Commissioning Board (operating under the name of NHS England)
10 contracts
0%

Geography

Distribution of awarded value by buyer region.

✓ From notices
UK · schematic only
Yorkshire95 contracts
98%
London4 contracts
2%
Wales21 contracts
0%
Scotland41 contracts
0%
Northern Ireland6 contracts
0%
North West10 contracts
0%

Peers

Suppliers with overlapping CPVs & buyers (last 24m). TEVA UK LIMITED highlighted.

✓ From notices
SupplierSME?Awarded · 24mContracts
TU
TEVA UK LIMITED
No£2.2bn—
AH
Alcura Healthcare Ltd.
No£18.7m1
MI
Medline Industries Limited
Yes£10.2m11
GM
GS Medical Healthcare Ltd
Yes£10.2m5
IM
Ideal Medical Solutions
Yes£10.2m10
SU
Stryker UK Limited
Yes£9.1m6
Compare peers →

Red flags · 0 active

Automated scan of Companies House status, charges and insolvency records.

✓ Verified
✓ Clean. No active risk signals from Companies House status, charges or insolvency records.

Compliance scorecard

Derived from Companies House filings — not a full supplier-assurance check.

↔ Cross-checked
Trading status
Active
Live at Companies House
Annual accounts
Up to date
Last made up to 31 Dec 2024
Confirmation statement
Up to date
Next due 28 Jan 2027
Outstanding charges
0
No charges registered
Insolvency history
None
No insolvency cases registered
Certifications (ISO, Cyber Essentials, Living Wage, B-Corp, modern-slavery) are supplier self-reported and appear once a claimed profile adds them.

Modifications

Variations to awarded contracts logged under Procurement Act 2023 s.74.

✓ From notices
±

No modifications recorded

No published contract variations for this supplier. Modification notices appear here as they are issued under the Procurement Act 2023.

News mentions

UK trade press & nationals, matched to this supplier.

◰

No news mentions found

We haven't matched any recent UK press coverage to this supplier. Mentions appear here automatically as they're published.

Companies House

Live sync — registered details, directors, PSC and SIC codes.

✓ Live sync

Registered details

Company no.
00302461
Status
Active
Type
Private limited
Incorporated
01 Jul 1935
Reg. office
Ridings Point, Whistler Drive, Castleford, England, WF10 5HX
SIC codes
21200
Last accounts
31 Dec 2024
Next accounts due
30 Sept 2026

Directors & PSC

  • CHARLESWORTH, Stephen Michael — director
    Appointed 29 Apr 2020
  • INNES, Kim — director
    Appointed 27 Sept 2016
  • Teva Pharma Holdings Limited — person with significant control
    ownership of shares 75 to 100 percent · voting rights 75 to 100 percent · right to appoint and remove directors

Financial

Filed accounts from Companies House.

↔ From Cos House
£

No financial filings on record

Turnover, profit and headcount appear here once audited or micro-entity accounts are filed at Companies House.

Org tree

Group structure and ownership.

↔ From Cos House
TEVA UK LIMITED
00302461 · this company

Independent. No parent company or subsidiaries recorded at Companies House for this entity.